ArticlePharmaceutics2025

Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma.

Rubén Osuna-Gómez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.